vTv Therapeutics Inc. (NASDAQ:VTVT) stock is trading lower on Monday. The FDA has placed a clinical hold on the cadisegliatin clinical program, which includes the ongoing CATT1 Phase 3 trial in type 1 ...
About four months into the job, Deepa Prasad is resigning from the top perch at vTv Therapeutics after restructuring the company to focus on a late-stage Type 1 diabetes med and laying off a majority ...
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead ...
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals, a ...
CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months vTv Therapeutics expects to resume the trial ...
-Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients TTP399 is a novel, oral, liver-selective ...
* VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES * VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 ...
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results